The safest are topicals
ProHealth Longevity BPC-157 is one of the products under the spotlight
Description Description A two-component co-formulation of cagrilintide and a GLP-1class peptide supplied for controlled research environments
Limitation of Liability By using this website, you agree that Alpha Rejuvenation, its employees, or affiliates are not responsible for any decision made or action taken based on the information given on this website
### Standard Reconstitution Ratios | Vial Size | BAC Water Added | Concentration | Dose 1mg = | Dose 2mg = | Dose 4mg = | |-----------|-----------------|---------------|------------|------------|------------| | **6mg** | 1.0mL | 6mg/mL | 0.17mL (17 units) | 0.33mL (33 units) | 0.67mL (67 units) | | **6mg** | 2.0mL | 3mg/mL | 0.33mL (33 units) | 0.67mL (67 units) | 1.33mL (133 units)* | | **10mg** | 1.0mL | 10mg/mL | 0.10mL (10 units) | 0.20mL (20 units) | 0.40mL (40 units) | | **10mg** | 2.0mL | 5mg/mL | 0.20mL (20 units) | 0.40mL (40 units) | 0.80mL (80 units) | | **12mg** | 2.0mL | 6mg/mL | 0.17mL (17 units) | 0.33mL (33 units) | 0.67mL (67 units) | | **12mg** | 3.0mL | 4mg/mL | 0.25mL (25 units) | 0.50mL (50 units) | 1.0mL (100 units) | | **20mg** | 2.0mL | 10mg/mL | 0.10mL (10 units) | 0.20mL (20 units) | 0.40mL (40 units) | | **20mg** | 4.0mL | 5mg/mL | 0.20mL (20 units) | 0.40mL (40 units) | 0.80mL (80 units) | | **24mg** | 3.0mL | 8mg/mL | 0.125mL (12.5 units) | 0.25mL (25 units) | 0.50mL (50 units) | | **30mg** | 3.0mL | 10mg/mL | 0.10mL (10 units) | 0.20mL (20 units) | 0.40mL (40 units) | | **30mg** | 6.0mL | 5mg/mL | 0.20mL (20 units) | 0.40mL (40 units) | 0.80mL (80 units) | | **40mg** | 4.0mL | 10mg/mL | 0.10mL (10 units) | 0.20mL (20 units) | 0.40mL (40 units) | | **50mg** | 5.0mL | 10mg/mL | 0.10mL (10 units) | 0.20mL (20 units) | 0.40mL (40 units) | | **60mg** | 6.0mL | 10mg/mL | 0.10mL (10 units) | 0.20mL (20 units) | 0.40mL (40 units) | *Units over 100 require a 2mL syringe
Inherited forms of the diseases which cause or are associated with dementia that may treated as described herein include but are not limited to: frontotemporal lobar degeneration, Huntington's disease, vascular dementia, dementia pugilistica, etc
